SI9300616A - Enzyme inhibitors - Google Patents

Enzyme inhibitors Download PDF

Info

Publication number
SI9300616A
SI9300616A SI9300616A SI9300616A SI9300616A SI 9300616 A SI9300616 A SI 9300616A SI 9300616 A SI9300616 A SI 9300616A SI 9300616 A SI9300616 A SI 9300616A SI 9300616 A SI9300616 A SI 9300616A
Authority
SI
Slovenia
Prior art keywords
isothiourea
ethyl
methyl
amino
group
Prior art date
Application number
SI9300616A
Other languages
English (en)
Slovenian (sl)
Inventor
Edward Patrick Garvey
Gerald Joseph Tanoury
Jeffrey Alan Oplinger
Eric Steven Furfine
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929224948A external-priority patent/GB9224948D0/en
Priority claimed from GB939315159A external-priority patent/GB9315159D0/en
Priority claimed from GB939319663A external-priority patent/GB9319663D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SI9300616A publication Critical patent/SI9300616A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9300616A 1992-11-27 1993-11-26 Enzyme inhibitors SI9300616A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929224948A GB9224948D0 (en) 1992-11-27 1992-11-27 Nitric oxide synthase inhibitors
GB939315159A GB9315159D0 (en) 1993-07-22 1993-07-22 Nitric oxide synthase inhibitors
GB939319663A GB9319663D0 (en) 1993-09-23 1993-09-23 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
SI9300616A true SI9300616A (en) 1994-06-30

Family

ID=27266488

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300616A SI9300616A (en) 1992-11-27 1993-11-26 Enzyme inhibitors

Country Status (7)

Country Link
EP (1) EP0670720A1 (ja)
JP (1) JPH08503940A (ja)
CN (1) CN1095710A (ja)
AU (1) AU5533094A (ja)
IL (1) IL107771A0 (ja)
SI (1) SI9300616A (ja)
WO (1) WO1994012165A2 (ja)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL180081B1 (pl) * 1993-08-12 2000-12-29 Astra Ab Nowe pochodne amidyny i sposób ich wytwarzania PL PL PL PL PL PL PL
AU688811B2 (en) * 1993-10-21 1998-03-19 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
CA2188680A1 (en) * 1994-05-07 1996-01-25 James Edwin Macdonald Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
GB9418912D0 (en) * 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
AU4149696A (en) * 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
WO1996018617A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
JPH08333258A (ja) 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
DE19530870A1 (de) * 1994-12-14 1996-06-20 Japan Tobacco Inc Thiazin- oder Thiazepinderivate
DE4444930A1 (de) * 1994-12-16 1996-06-27 Cassella Ag 2-Amino-1,3-thiazepine und deren Verwendung als Hemmstoffe der Stickstoffmonoxid-Synthase
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
TW397812B (en) * 1995-02-11 2000-07-11 Astra Ab Bicyclic isothiourea derivatives useful in therapy
FR2730733B1 (fr) * 1995-02-17 1997-07-04 Hoechst Lab Nouveaux derives nitro-ethyleniques soufres et leurs applications en tant qu'inhibiteurs de no-synthase
US5929063A (en) * 1995-03-24 1999-07-27 Children's Hospital Medical Center Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
US5674907A (en) * 1995-03-24 1997-10-07 Children's Hospital Medical Center Mercapto derivatives as inhibitors of nitric oxide synthase
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
CA2216882A1 (en) * 1995-04-20 1996-10-24 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
EP1067926A2 (en) * 1998-04-06 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
JP2002517502A (ja) 1998-06-10 2002-06-18 ジー・ディー・サール・アンド・カンパニー 複素二環状及び三環状一酸化窒素シンターゼ阻害剤
US6552052B2 (en) 1998-06-10 2003-04-22 Monsanto/G.D. Searle Pyrrolo[2,1-c][1,2,4] thiadiazoles and Pyrollo[2,1-c][1,12,4]oxadiazoles useful as nitric oxide synthase inhibitors
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
BRPI0108024B8 (pt) * 2000-01-19 2021-05-25 Cadila Healthcare Ltd composto, processo para a preparação de um composto, composição farmacêutica, uso do composto, novo intermediário e processo para a preparação de um novo intermediário
ZA200206459B (en) 2000-03-24 2003-08-13 Pharmacia Corp Amidino compound and salts thereof useful as nitric oxide synthase inhibitors.
US7087633B2 (en) 2000-03-31 2006-08-08 Universitair Medisch Centrum Method for treating perinatal asphyxia in a human or animal neonate
ATE296627T1 (de) * 2000-03-31 2005-06-15 Univ Medisch Centrum Utrecht Verwendung von 2-iminobiotin zur herstellung eines arzneimittels zur prävention und / oder therapie von komplikationen bei neugeborenen, die während der geburt entstanden sind
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6956131B2 (en) 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6420566B2 (en) 2000-06-09 2002-07-16 Aventis Pharma S.A. Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof
FR2832152A1 (fr) * 2001-11-09 2003-05-16 Aventis Pharma Sa Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible
FR2810036B1 (fr) * 2000-06-09 2004-04-23 Aventis Pharma Sa Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant
FR2810037B1 (fr) * 2000-06-09 2004-04-23 Aventis Pharma Sa Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible
US6451821B1 (en) 2000-06-09 2002-09-17 Aventis Pharma S.A. Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
ES2250731T3 (es) 2001-11-09 2006-04-16 Aventis Pharma S.A. Derivados de 2-amino-4-heteroariletil tiazolina y su utilizacion como inhibidores de no-sintasa inductible.
FR2832151B1 (fr) * 2001-11-09 2004-12-17 Aventis Pharma Sa Utilisation de derives de 2-amino-4-heteroarylethyl-thiazoline comme inhibiteurs de no-synthase inductible
JP4342309B2 (ja) 2001-11-09 2009-10-14 アベンティス・ファーマ・ソシエテ・アノニム 誘導型ｎｏ−シンターゼ阻害剤としての２−アミノ−４−ピリジルメチル−チアゾリン誘導体の使用
FR2832150B1 (fr) * 2001-11-09 2004-07-16 Aventis Pharma Sa Utilisation de derives de 2-amino-4-pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible
JP2005526005A (ja) * 2001-11-09 2005-09-02 アベンティス・ファーマ・ソシエテ・アノニム 誘導型ｎｏシンターゼの阻害剤としての２−アミノ−チアゾリン誘導体及びその使用
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
WO2007108004A2 (en) * 2006-03-23 2007-09-27 Meditor Pharmaceuticals Ltd. S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
CN101372471B (zh) * 2008-10-08 2010-12-22 中国科学院化学研究所 烷基异脲类化合物及其类似物的新用途
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
TW201040141A (en) 2009-03-31 2010-11-16 Shionogi & Co Isothiourea derivatives or isourea derivatives having BACE1 inhibitory activity
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
WO2012057248A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 ナフチリジン誘導体
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1178242A (en) * 1966-02-05 1970-01-21 Wellcome Found Novel Biologically Active Bis-Isothioureas
US3790600A (en) * 1972-04-06 1974-02-05 Uniroyal Inc 2-(3-benzo(b)thenyl)-2-thiopseudourea and its pharmaceutically acceptable salts
US3954982A (en) * 1972-04-20 1976-05-04 Smith Kline & French Laboratories Limited Pharmaceutical compositions and method of inhibiting H-1 and H-2 histamine receptors
ZA771408B (en) * 1976-03-29 1978-04-26 Smith Kline French Lab Pharmaceutical compositions
US4208430A (en) * 1979-03-15 1980-06-17 Smithkline Corporation Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase
US4262125A (en) * 1979-07-23 1981-04-14 American Home Products Corporation (1H-Imidazol-5-ylmethyl)isothioureas
EP0245669B1 (de) * 1986-05-14 1993-12-01 Medopharm Arzneimittelwerk Dr. Zillich GmbH & Co. Pharmazeutisches Präparat zur Verhütung der Schädigung lebender Zellen durch freie Radikale, beziehungsweise zur Erhöhung der Wirksamkeit von organischen Schwefelverbindungen und Verfahren zur Erhöhung der Lebensdauer isolierter Organe
GB8916947D0 (en) * 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
CA2066728C (en) * 1989-09-19 2001-12-25 Jan K. Hellstrand Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
ATE191847T1 (de) * 1991-12-16 2000-05-15 Univ Washington Verwendung von aminoguamidin zur herstellung eines arzneimittels zur unterdrückung der stickoxidbildung
KR100892685B1 (ko) * 2007-11-09 2009-04-15 주식회사 하이닉스반도체 Ｅａｉｃ 시스템

Also Published As

Publication number Publication date
EP0670720A1 (en) 1995-09-13
WO1994012165A2 (en) 1994-06-09
CN1095710A (zh) 1994-11-30
JPH08503940A (ja) 1996-04-30
WO1994012165A3 (en) 1994-12-08
AU5533094A (en) 1994-06-22
IL107771A0 (en) 1994-02-27

Similar Documents

Publication Publication Date Title
SI9300616A (en) Enzyme inhibitors
ES2343481T3 (es) Antagonistas del receptor cgrp.
JPH09504278A (ja) Ｎｏシンターゼインヒビターとしての置換尿素およびイソチオ尿素誘導体
CA2520855C (fr) Derives d'imidazo-pyridine comme agonistes ou antagonistes du recepteur de la melanocortine
US20220288070A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
SU1400508A3 (ru) Способ получени производных арилтиазолов
WO1996014842A1 (en) Substituted heterocycles as inhibitors of nitric oxide synthase
US20230242505A1 (en) Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
EA008865B1 (ru) Производные 2-имино-4-оксотиазолидина
US8357707B2 (en) 2-carboxamide cycloamino ureas
EP3738954A1 (en) Method of preparation of substituted 2,4-diamino-pyrimidine-5-carboxamides
CA3143508A1 (en) Hck degraders and uses thereof
EP3845538B1 (en) Dihydroimidazopyrazinone compound, composition including same, and use thereof
EP3353170A1 (en) New benzimidazoles derivatives as tec kinases family inhibitors
JP6985271B2 (ja) アルキニルジヒドロキノリンスルホンアミド化合物
EP3390392B1 (en) Alkyl dihydroquinoline sulfonamide compounds
KR20070114822A (ko) 조혈기 종양 치료제
AU2003238915B2 (en) (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
NZ188770A (en) Thiazolinylguanidine derivatives and pharmaceutical compositions
RU2168493C2 (ru) Производные l-аргинина, способ их получения, фармацевтическая композиция, обладающая ингибирующей no-синтазу активностью
US11993613B2 (en) Thiazolo[5,4-b]pyridine MALT-1 inhibitors
US6090846A (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
US6225305B1 (en) Substituted urea and isothiorea derivatives as no synthase inhibitors
US6297276B1 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
US3398144A (en) Substituted 3-amino-2'-hydroxyacrylophenones